BLCO - Mergers and acquisitions

Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that an affiliate has acquired Elios Vision, Inc., developer of the ELIOS™ procedure, the first clinically validated, minimally invasive glaucoma surgery (MIGS) procedure using an excimer laser. The acquisition unlocks new opportunities to treat glaucoma effectively in conjunction with cataract surgery without implants and bolsters Bausch + Lomb's glaucoma portfolio, which features pharmaceutical and surgical approaches. "Today's announcement further demonstrates our commitment to investing in smart, innovative technologies that enable eye c

Acquisition Will Enhance Bausch + Lomb's Surgical Portfolio with IC-8® Apthera™ Intraocular Lens Bausch + Lomb Corporation (TSX:BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, and AcuFocus, Inc. ("AcuFocus"), a privately held ophthalmic medical device company, today announced that an affiliate of Bausch + Lomb has acquired AcuFocus, pursuant to a merger transaction with the parent company of AcuFocus. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230116005387/en/ AcuFocus has delivered breakthrough small aperture intraocular technology to address the diverse un